Expertise in
3
conditions

Cornelia Liedtke-Kolberg

Bochum, NW, DE 
Expertise in
3
conditions
Bochum, NW, DE 

Overview

Cornelia Liedtke-Kolberg practices practicing medicine in Bochum, Germany.

Ms. Liedtke-Kolberg is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, BRCA Positive Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Mastectomy.

She is actively involved in clinical research, co-authoring 64 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Bochum, NW, Germany
Other Locations
Essen, NW, Germany
Wiesbaden, HE, Germany
Berlin, BE, Germany
Mitte, BE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY / BREVITY-02 in Germany)
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY / BREVITY-02 in Germany)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2026
Intervention Type: Procedure
Study Phase: Not Applicable
A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype
A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype
Enrollment Status: Completed
Publish Date: May 15, 2023
Intervention Type: Drug
Study Drugs: Pembrolizumab, Trastuzumab Biosimilar ABP 980, Pertuzumab
Study Phase: Phase 2
View 1 Less Clinical Trial

64 Total Publications

Early pregnancy loss: A survey of healthcare experiences and perceived support in Germany.
Early pregnancy loss: A survey of healthcare experiences and perceived support in Germany.
Journal: Sexual & reproductive healthcare : official journal of the Swedish Association of Midwives
Published: July 31, 2025

Frequently Asked Questions about Cornelia Liedtke-Kolberg

Is Cornelia Liedtke-Kolberg a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Cornelia Liedtke-Kolberg is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Cornelia Liedtke-Kolberg participate in research or clinical trials?

Yes. Cornelia Liedtke-Kolberg has published 64 articles and abstracts on conditions like Breast Cancer. You can view a list of Cornelia Liedtke-Kolberg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Liedtke-Kolberg's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile